Biocon Ltd continued its upward momentum on Thursday, with the stock climbing nearly 3% to a fresh 52-week high of ₹447 after receiving a major regulatory approval from the European Medicines Agency (EMA).

Shares Hit Fresh 52-Week High as European Approval for Semglee Manufacturing, Mylan's Exit and Positive Technical Indicators Boost Investor Confidence

Biocon Ltd continued its upward momentum on Thursday, with the stock climbing nearly 3% to a fresh 52-week high of ₹447 after receiving a major regulatory approval from the European Medicines Agency (EMA). The approval allows the company to manufacture and supply Semglee (Insulin Glargine) from its newly approved fill-finish line at its insulin manufacturing facility in Malaysia, marking another important milestone in Biocon's global biosimilars business.

The latest development comes just days after global pharmaceutical company Mylan, a subsidiary of Viatris, exited its entire stake in Biocon through a large block deal. The removal of this long-standing supply overhang, combined with strong buying by leading domestic and foreign institutional investors, has significantly improved market sentiment toward the stock.

Over the last three trading sessions, Biocon shares have rallied nearly 9%, outperforming the broader market and moving closer to their all-time high of ₹487.70 recorded in December 2020.

EMA Approval Strengthens European Expansion Strategy

The biggest trigger behind Thursday's rally was the European Medicines Agency's approval of Biocon's new manufacturing line for Semglee, a biosimilar version of insulin glargine used in diabetes treatment.

According to the company, commercial supplies from the newly approved Malaysian facility are expected to commence during Q2 FY27.

The approval is strategically significant because it:

Expands Biocon's manufacturing capacity.
Enhances supply chain flexibility for European markets.
Supports growing demand for biosimilar insulin products.
Improves production efficiency through an integrated manufacturing network.
Reinforces the company's compliance with stringent European quality standards.

The approval also demonstrates Biocon's growing capabilities as a global biopharmaceutical manufacturer serving regulated international markets.

Stock Extends Rally After Institutional Buying

Biocon shares have witnessed renewed investor interest following the complete exit of Mylan, which sold its 5.64% stake in the company through a block deal worth approximately ₹3,679 crore.

Instead of creating prolonged selling pressure, the transaction was comfortably absorbed by several large institutional investors.

Major buyers reportedly included:

ICICI Prudential Mutual Fund
HDFC Mutual Fund
SBI Mutual Fund
Kotak Mahindra Mutual Fund
Morgan Stanley Asia Singapore

The successful placement has removed a significant technical overhang and improved liquidity in the stock, encouraging fresh buying from institutional as well as retail investors.

Technical Charts Indicate Improving Momentum

Market technicians believe Biocon's price structure has turned increasingly constructive.

According to technical analysts, the recent rally has been accompanied by several positive indicators:

Key Technical Signals

Increase in futures open interest.
Long additions in derivatives positions.
Rising Put-Call Ratio (PCR).
Strong price-volume breakout.
Institutional accumulation after the block deal.

The improvement in derivatives positioning suggests growing confidence among professional traders, while sustained buying above recent resistance levels may provide further support to the ongoing rally.

If the stock maintains momentum above current levels, analysts believe it could gradually move toward its previous lifetime high over the medium term.

Biosimilars Business Continues to Lead Growth

Biocon's biosimilars division remains the company's primary long-term growth engine.

The company has steadily expanded its presence across regulated global markets by focusing on:

Commercial execution.
New product launches.
Market access expansion.
Regulatory approvals.
Manufacturing scale.

Management highlighted in its FY26 Annual Report that products launched during the previous financial year are expected to contribute more meaningfully during FY27 as commercialisation accelerates across international markets.

The company also expects increasing operating leverage from its vertically integrated manufacturing platform, supporting profitability in coming quarters.

Generics Business Positioned for Stable Growth

Alongside biosimilars, Biocon's generics segment is also expected to deliver steady performance during FY27.

Growth drivers include:

Expanding Product Portfolio

The company continues to introduce new generic formulations across regulated markets.

Higher Production Volumes

Existing manufacturing facilities are expected to operate at higher utilisation levels.

Cost Optimisation

Operational efficiency initiatives remain a major focus area.

Vertical Integration

Integrated manufacturing capabilities continue to provide cost advantages over many competitors.

Although pricing pressure remains a challenge across global generic pharmaceutical markets, Biocon believes scale and operational discipline will remain key competitive strengths.

Europe Remains a Strategic Market

Europe continues to be one of the most attractive growth markets for biosimilar manufacturers.

Several structural factors support demand:

Rising healthcare costs.
Increasing adoption of biosimilars.
Government initiatives to reduce treatment expenses.
Greater acceptance of affordable biologic medicines.

The EMA approval further strengthens Biocon's ability to capitalise on these long-term opportunities.

FY27 Growth Drivers

Management remains optimistic regarding the company's outlook for the current financial year.

Key growth catalysts include:

Commercial Scaling of New Launches

Products approved during FY26 are expected to contribute meaningfully to revenues.

Manufacturing Expansion

New production facilities will improve supply capacity.

Regulatory Milestones

Additional approvals across regulated markets could further expand the addressable market.

Margin Improvement

Operating leverage from higher production volumes may support profitability.

Global Biosimilars Opportunity

Demand for affordable biologic therapies continues to increase worldwide.

Challenges That Investors Should Monitor

Despite the favourable outlook, investors should remain aware of potential risks.

These include:

Pricing pressure in generic medicines.
Regulatory approval delays.
Currency fluctuations affecting overseas earnings.
Increasing competition from global biosimilar manufacturers.
Execution risks during commercial expansion.

The pharmaceutical industry remains highly regulated, making compliance and execution critical for sustained growth.

Valuation and Market Sentiment

Biocon's recent rally reflects growing confidence in its long-term fundamentals rather than short-term speculation alone.

The combination of:

Regulatory approvals.
Institutional accumulation.
Manufacturing expansion.
Global product pipeline.
Strong technical indicators.

has strengthened investor sentiment toward the company.

However, following the sharp appreciation over the past few sessions, some volatility cannot be ruled out as traders may choose to book profits.

Should Investors Buy, Hold or Book Profits?

Biocon appears to be entering a favourable phase driven by improving operational execution, expanding manufacturing capabilities and strong momentum in its biosimilars business. The EMA approval significantly enhances the company's ability to serve European markets, while the removal of Mylan's stake overhang has improved the stock's technical outlook.

For existing long-term investors, the company's expanding global footprint, vertically integrated manufacturing model and robust biosimilars pipeline continue to support a positive investment case. Fresh investors, however, may consider accumulating the stock gradually rather than chasing prices after a sharp rally, as near-term volatility cannot be ruled out.

Outlook

Biocon's latest regulatory success reinforces its ambition to become one of the leading global biosimilars companies. With manufacturing capacity expanding, institutional ownership strengthening and multiple product launches expected to scale during FY27, the company enters the new financial year with strong operational momentum. While short-term movements may depend on broader market conditions and quarterly earnings, the long-term outlook remains supported by increasing global demand for affordable biologic therapies, continued regulatory progress and Biocon's growing presence in regulated international markets.